| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 615.20 | 2.2% | 23.4% |
| Total Income | 617.78 | 2.4% | 23.5% |
| Expenditure | 529.73 | 1.4% | 18.5% |
| PBT | 88.05 | 9.4% | 64.6% |
| Net Profit | 64.18 | 15.5% | 81.6% |
| OPM | 19.18% | 0.79pp | 4.72pp |
| NPM | 10.39% | 1.18pp | 3.33pp |
| EPS | 5.42 | 15.6% | 81.3% |
Record PAT Growth Masks a Revenue Engine at 2% Organic
Profit jumped 81.6% but only 2% came from organic revenue growth. Acquisition, FX, and margin expansion did the lifting — and the street isn't buying the growth story yet.
₹64.2 Cr
+81.6% YoY
₹66.5 Cr
+53% YoY
+23.4%
Only 2% organic
20.2%
vs 18–19% target
R Systems' Q2 PAT jumped 81.6% to ₹64.2 Crore — a headline demanding scrutiny. Dig one layer and the picture inverts: organic revenue grew just 2%, well below the 3–4% aspiration management restated a quarter ago, and TTM ACV bookings are flat despite the AI push. The profit is real, but it rests on margin expansion (20.2% EBITDA, beating guidance) and a ~₹7 Crore FX tailwind — not revenue acceleration.
What drove the 81.6% PAT jump
Reported PAT grew ₹29 Crore. Of that, organic revenue growth (2%) contributed maybe ₹1 Crore. Margin expansion — EBITDA margin moving from 16.9% to 20.2% on a larger nominal base — added roughly ₹20 Crore. FX tailwind (~₹7 Cr acknowledged) added another ₹7 Crore. Adjusted PAT ₹66.5 Crore (+53% YoY) is the cleaner organic proxy: profit grew sharply, but on operational discipline and currency help, not on growing the revenue line.
What management claimed vs. what holds up
23.4% YoY revenue growth, strong momentum
Overstated₹615.2 Cr vs ₹498.6 Cr LY. But organic +2% only; Novigo acquisition & FX tailwind account for 21 percentage points of the reported 23.4% growth.
7 continuous quarters of growth & margin improvement
SupportedPAT +81.6%, OPM 19.2% vs 16.9% LY, adjusted EBITDA 20.2% vs prior 16.9%. All confirmed.
TTM ACV bookings momentum, strong pipeline
Mixed₹82.9M TTM ACV unchanged YoY. Management acknowledged flatness; attributed to strategic shift from many small to fewer large transformational deals (longer 3–4 month cycles).
AI revenue >35%, EXIOO/agentic traction
PartialClaimed 'probably well over 35%' of revenue but unaudited. Early wins named (telecom modernization, finserv automation, insurance, entertainment). Tone confident, data unverified.
What changed on this call
Management pivoted strategy explicitly: from pure IT services/OPD to enterprise transformation and agentic AI. The EXIOO studio is live; large client wins in telecom, financial services, entertainment, and insurance are named and material. But the operational reality is concrete: deal cycles have extended to 3–4 months, and ACV counts are flat. Enterprise revenue is still ~15% of total (target: 25–35% in 2–3 years), so this is early-stage. Most materially, management dropped the 3–4% constant-currency growth aspiration and admitted Q2 organic is 2%, blamed on deal timing and cycle lengthening. That is an implicit guidance cut, even though unstated.
The bull-bear ledger
PAT +81.6%, margin beats target, 7 quarters of consistent growth
EBITDA 20.2% is above the 18–19% aspiration; operational leverage proven
Enterprise/AI strategy credible; named wins in verticals with clear ROI (telecom modernization, finserv automation)
Organic revenue growth stalled at 2%, vs prior 3–4% aspiration
TTM ACV bookings flat; deal cycle lengthening delays revenue and execution risk
AI revenue unaudited; >35% claim lacks third-party verification
Margin already at 20.2%, above target; limited upside buffer for further expansion
Geopolitical uncertainty (Middle East); Novigo integration ongoing
Risks, ranked by how much they should concern a holder
Organic growth stalled at 2% vs 3–4% prior target; no recovery timeline given
HighIf organic doesn't reach 4%+ in the next 2 quarters, the growth narrative collapses entirely. Margin expansion alone cannot drive re-rating; revenue growth must inflect. Management hired a Chief Revenue Officer 2 qtrs ago but results not yet visible. Monitor Q3 organic growth — this is the line item that matters.
ACV bookings flat; deal cycles extending to 3–4 months
HighDeal count hasn't recovered. The shift to larger transformation deals is strategic, but flat bookings despite AI/enterprise focus signals weak pipeline or poor conversion. Q3/Q4 results will reveal whether deals are delayed or truly slowing. This is a bellwether.
Novigo integration, geopolitical headwind (Middle East)
MediumNovigo (Saudi Arabia, UAE) is ~4% of revenue and growing, but management flagged 'tentativeness' in the Middle East due to conflict. If Novigo stalls, a 4–5% revenue headwind emerges in FY28. Track this separately in Q3 commentary.
Margin plateau at 20.2%; upside buffer limited
MediumEBITDA is already above target (20.2% vs 18–19%). Management restated 'high 18s' (18.6–18.7%) as sustainable, suggesting 20%+ is not reliable. If organic growth stays at 2%, margin becomes the only story — and that's a ceiling, not a runway.
AI revenue unaudited; >35% claim unverified
MediumManagement said 'probably' when asked if AI is >35% of revenue; no audit trail. Segmentation changes could inflate the percentage without genuine new wins. This resolves or escalates once 3–4 quarters of formal tracking exist.
How the street is positioned
The stock trades at ₹264.3, below its 200-day average (₹270.33) and well below its 52-week high of ₹430.2 — a 55.88% drawdown from the peak. It sits above the 20-day and 50-day averages, suggesting modest recovery after the broader selloff. Volume is increasing, which can signal either accumulation or capitulation. FII holdings are effectively flat (3.82% in Q1 FY27 vs 3.76% a quarter ago), while DII trimmed 2.07 percentage points (from 8.60% to 6.53%). The bulk deals from early October show mixed activity — institutional players alternating buys and sells at ₹271–₹274 — but nothing dramatic or sustained. The market is treating this as a steady-state IT services operator, not a turnaround or growth inflection. That positioning is consistent with our fundamental read: profit is strong, but growth is stuck.
1 · Q3 organic revenue growth
The linchpin. If organic stays at 2%, the growth thesis breaks; if it reaches 3–4%+, the deal cycle lengthening was real timing delay. Monitor this number closely — it is the single metric that resolves the debate.
2 · ACV bookings and deal win rate
Track TTM ACV in Q3. If bookings remain flat but enterprise/AI revenue inflects (proving cycle delays are real), the risk lowers. If both stay flat, pipeline quality or conversion is in question.
3 · Enterprise revenue mix and deal size
Confirm the shift to larger transformational deals is real. If enterprise revenue reaches 18–20% of total in Q3, the strategy is working; if it stalls at 15%, the pivot has stalled too.
R Systems delivered a strong profit quarter — adjusted PAT up 53% driven by margin expansion and operational discipline. But the revenue engine is running on 2% organic growth, well below management's prior aspirations and below what the market calls inflection. The enterprise/AI transformation pivot is real and strategically sound; named wins in verticals with clear ROI are credible. But they're early wins, not scaled revenue yet. The next 2 quarters will tell whether this is a quarter-long timing delay or a structural slowdown. Until organic growth re-inflects toward mid-single digits, this remains a steady, well-managed company at a margin ceiling — not a growth story. Track the organic growth number from here.
Strong PAT growth masks stalled organic revenue; AI inflection pending
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered margin above 18–19% target; organic growth ~2% vs prior 3–4% aspiration. No formal quantitative guidance issued or missed.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong profit delivery (+81.6% PAT, 20.2% EBITDA margin beats guidance) masks a stalling organic growth engine (2% admitted). AI/enterprise transformation thesis is credible with named wins, but unproven at scale and 2–3 years out. Key risk: if organic growth doesn't inflect to mid-single digits within 2 quarters, margin expansion is the only story, and sentiment turns cautious.
₹615.2 Cr
Revenue · +23.4% YoY₹64.2 Cr
Reported PAT · +81.6% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
23.4% YoY revenue growth, strong momentum
OVERSTATED₹615.2 Cr vs ₹498.6 Cr LY; organic +2%, rest FX/Novigo mix
7 continuous quarters of growth, margin improvement
METDelivered: +81.6% PAT, 20.2% OPM vs 16.9% LY; holds
Adjusted EBITDA 20.2%, sustainable margin strategy
MET₹124.4 Cr adjusted EBITDA at 20.2% vs 16.9% LY, above 18–19% target
TTM ACV bookings ₹82.9M, bookings momentum strong
MixedStated but flagged as 'flat' by management; shift from many small to fewer large deals
AI revenue >35%, agentic AI/EXIOO gaining traction
PartialStated 'probably well over 35%' but not audited; early wins named (telecom, finserv, insurance)
Earnings quality
What changed since the last call
Enterprise/AI positioning
UpgradeShifted from pure tech/OPD to agentic AI, PDLC, modernization. Large client wins named (telecom, finserv, entertainment, insurance). AI revenue now 35%+ vs early stage prior year.
ACV/bookings trajectory
DowngradeTTM ACV bookings flat (₹82.9M); management acknowledged pressure. Shift to larger, longer-duration deals delays revenue recognition; deal duration now 3–4 months vs prior.
Margin target reaffirmed
NeutralMgmt restated 18–19% adjusted EBITDA as sustainable; Q2 delivered 20.2%, above target. Suggests conservatism or prior mix improvement.
Organic growth admission
DowngradeManagement candid: 2% organic growth this quarter, vs prior 3–4% aspiration. Blamed deal timing, not capability. This is materially below prior guidance.
The Q&A
Moderate pushback on growth stall and ACV flatness. Anmol Garg (DAM) pressed on high-tech margin and ACV; Sandeep Shah (Equirus) on organic acceleration timeline; Vinay Menon (Monarch) on margin ceiling. Management held to strategy narrative (AI/enterprise shift justifies lower ACV count, longer cycles), but provided no acceleration timeline. No evasion; tone factual, slightly defensive on growth rate.
Portfolio mix and productivity — Anmol Garg, DAM Capital
AnsweredPressure is real due to AI PDLC adoption; our approach is proactive—AI-enabled models deliver 2–3x productivity, allowing us to reprice renewals and win new work with enhanced commitment.
TTM ACV and growth trajectory — Anmol Garg, DAM Capital
PartialACV flatness is by design—fewer, larger transformational deals replace many small ones. Deal duration 3–4 months, revenue density higher. Organic 2%, but pipeline quality improving. We're winning on right motions, will reach double digits.
Organic growth rate — Sandeep Shah, Equirus Securities
PartialOrganic +2% is lower than expectation due to deal timing; some Q2 deals shifted to Q3/Q4. This is a quarter thing, not structural. Deal conversion time longer due to agentic workflow adoption. For double-digit growth, industry needs to keep surprising.
Renewals and margin sustainability — Vinay Menon, Monarch Capital
AnsweredRenewals at 85%+ rate, steady. Margins: we stated 18–19% as sustainable; we're delivering 20.2%. We've carefully managed currency uplifts, won't consume them on investments. High 18s is our respectable, sustainable range.
Enterprise revenue and growth drivers — Aditya, AK Investment
AnsweredEnterprise is ~15% today, targeting 25–35% in 2–3 years. Growth will come from wallet share gains in larger accounts (transformation work) and new enterprise logos. ACV mix will shift; profitability per deal improves despite lower count.
BFSI and vertical health — Ashis Dash, Systematix Group
AnsweredBFSI is first-mover on AI PDLC and modernization. Healthcare/manufacturing have near-term project headwinds but strong AI/ML adoption trajectory. North America is largest market, will see highest growth with AI penetration.
Guidance
No explicit FY27 revenue target; organic growth aspiration low-to-mid single digits
LowPrior stated 3–4% constant-currency growth. Q2 delivered 2% organic, so below prior range. Management says 'double digits' is ambition, not near-term.
18–19% adjusted EBITDA sustained; high 18s (18.6–18.7%) respectable, sustainable
HighQ2 delivered 20.2%, above target. Management confident currency uplifts won't be spent; margin floor clear.
ESOP/RSU expense stable; SG&A as % of revenue to remain disciplined
MediumRSU expense ₹3.2Cr vs ₹6.2Cr prior Q (reduction). On-site hiring ramping for AI (FTE growth picking up North America).
Risks the call surfaced
Organic growth stall
HighOrganic growth 2% vs prior 3–4% aspiration. Deal timing delays cited, but no clear recovery timeline. If organic doesn't reach 4%+ in next 2 qtrs, growth narrative collapses despite margin strength.
ACV/bookings momentum
HighTTM ACV bookings flat at ₹82.9M. Shift from many small deals to fewer large transformational ones extends cycle to 3–4 months and defers revenue. If pipeline doesn't convert faster, Q3/Q4 could disappoint.
Geopolitical / Novigo
MediumNovigo (Middle East) contributed to revenue in last 3 qtrs; ongoing geopolitical uncertainty. Management flagged Middle East volatility affecting client engagement. If Novigo delays/stalls, a 4–5% revenue headwind emerges.
AI revenue verification
MediumAI revenue claimed at >35% of total (₹215+Cr), but not explicitly audited or detailed. Management said 'probably' when asked, and revenue mix shift could be driven by segmentation changes rather than genuine new wins.
Margin expansion plateau
LowEBITDA margin at 20.2%, above target of 18–19%. Management stated 18–19% as sustainable and respectable, suggesting further margin upside may be limited. If organic growth remains 2%, margin becomes the only growth story, creating valuation ceiling.
Management
Score 7/10. Clear, structured, candid on challenges (organic growth, ACV flatness, deal timing). Acknowledges risks (geopolitical, competition). Some hedging on growth acceleration (deferred to 'leading indicators'), but factual overall. Mixed: PAT +81.6%, margins beat, 7 quarters of growth delivered. Organic growth stalled at 2%, below prior aspiration. Enterprise sales motion launched but early. Execution credible on margin/profitability, weak on top-line growth.
1 · Q3/Q4 FY27
AI/agentic deal conversion — enterprise clients transition from pilots to production deployments
2 · FY28
Enterprise revenue inflection — targeting 25–35% mix (from 15%) as transformation work scales
3 · Next 2 qtrs
Organic growth acceleration — if pipeline converts, should move toward mid-single-digit or above
Key risk: if organic growth doesn't inflect to mid-single digits within 2 quarters, margin expansion is the only story, and sentiment turns cautious.